gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Uroplakin 2

uroplakin II, UPII, UPK2
This gene encodes one of the proteins of the highly conserved urothelium-specific integral membrane proteins of the asymmetric unit membrane which forms urothelium apical plaques in mammals. The asymmetric unit membrane is believed to strengthen the urothelium by preventing cell rupture during bladder distention. The encoded protein is expressed in the peripheral blood of bladder cancer patients with transitional cell carcinomas.[provided by RefSeq, Sep 2009] (from NCBI)
Top mentioned proteins: CAN, HAD, POLYMERASE, Tetraspanin, cytokeratin
Papers on uroplakin II
Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.
Rao et al., Oklahoma City, United States. In Cancer Prev Res (phila), Jan 2016
Six-week-old transgenic UPII-SV40T male mice (n = 15/group) were fed control diet (AIN-76A) or experimental diets containing mTOR inhibitor (rapamycin, 8 or 16 ppm), p53 stabilizing agent [CP31398 (CP), 150 ppm], or a combination.
Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
Cheng et al., Indianapolis, United States. In Appl Immunohistochem Mol Morphol, Nov 2015
Mouse monoclonal uroplakin II (UPII) and p40 antibodies have recently been developed and demonstrated high specificity in urothelial carcinoma.
Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder.
German study group of bladder cancers et al., Aachen, Germany. In J Clin Pathol, Nov 2015
METHODS: Tissue microarray sections of formalin-fixed, paraffin-embedded tissues from clinically verified 11 BAC, 11 CAC, 18 invasive urothelial carcinomas (UCs), 22 normal urothelium samples, 25 CC and 15 IM were stained for keratin 7, 5/6, 5/14 and 20, ß-catenin, e-cadherin, cadherin 17, cdx2, uroplakin II and III, CD10, androgen receptor (AR), S100P, MUC2, MUC5AC and GATA3 expression.
Urinary uroplakin expression in cyclophosphamide-induced rat cystitis model.
Lee et al., Ch'ŏnan, South Korea. In Hum Exp Toxicol, Oct 2015
We investigated the role of urinary uroplakin II (UPII) levels in a CYP-induced cystitis model.
Utility of uroplakin II expression as a marker of urothelial carcinoma.
Netto et al., Baltimore, United States. In Hum Pathol, 2015
Uroplakin II (UPII) is a newly described sensitive marker for urothelial carcinoma (UC).
TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma.
Rao et al., Oklahoma City, United States. In Am J Cancer Res, 2014
Transgenic UPII-SV40T male mice at 6weeks age (n=15/group) were fed control diet (AIN-76A) or experimental diets containing DFMO (1000 and 2000 ppm) or 150 ppm CP or both.
Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Guo et al., Houston, United States. In Am J Clin Pathol, 2014
Here we studied the sensitivity of UPII and UPIII in conventional and variant urothelial carcinomas (UCs).
Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.
Wang et al., Lanzhou, China. In Tumour Biol, 2014
Bladder cancer-specific oncolytic adenovirus Ad/PSCAE/UPII/E1A, carrying E1A gene regulated by human Uroplakin II (UPII) promoter and prostate stem cell antigen enhancer (PSCAE), could kill bladder tumor cells preferentially.
Evaluation of (99m)Tc-probestin SPECT as a novel technique for noninvasive imaging of kidney aminopeptidase N expression.
Gali et al., Oklahoma City, United States. In Mol Pharm, 2014
Abdominal SPECT imaging was conducted at 1 h postinjection of (99m)Tc-probestin in a group of 12 UPII-SV40T transgenic and wild-type mice.
Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.
Rao et al., Oklahoma City, United States. In Cancer Prev Res (phila), 2014
We determined the chemopreventive efficacy of licofelone, a dual COX-lipoxygenase (LOX) inhibitor, in a transgenic UPII-SV40T mouse model of urothelial transitional cell carcinoma (TCC).
A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
Cheng et al., Indianapolis, United States. In Arch Pathol Lab Med, 2014
CONTEXT: Uroplakin II is a 15-kDa protein component of the urothelial plaques that enhance the permeability barrier and strength of the urothelium.
SNX31: a novel sorting nexin associated with the uroplakin-degrading multivesicular bodies in terminally differentiated urothelial cells.
Sun et al., Beijing, China. In Plos One, 2013
SNX31 can bind, on one hand, the PtdIns3P-enriched lipids via its N-terminal PX-domain, and, on the other hand, it binds uroplakins as demonstrated by co-immunoprecipitation and proximity ligation assay, and by its reduced membrane association in uroplakin II-deficient urothelium.
Uroplakins do not restrict CO2 transport through urothelium.
Mathai et al., Linz, Austria. In J Biol Chem, 2012
role of uroplakins in CO2 transport through urothelium
Role and extent of lymphadenectomy during radical cystectomy for invasive bladder cancer.
Zehnder et al., San Antonio, United States. In Curr Urol Rep, 2012
Proteins associated purely with epithelial tissue such as cytokeratin (CK)-19, CK-20, and uroplakin II have been observed in reportedly negative nodal specimens, which indicates that routine microscopic analysis of nodal tissue may miss small foci of metastatic cancer.
Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis.
Tuohy et al., Cleveland, United States. In Eur Urol, 2012
Bladder-specific autoimmune response sufficient to induce inflammation and interstitial cystitis occurs in mice following immunization with recombinant murine UPK2.
Expression and localization of four uroplakins in urothelial preneoplastic lesions.
Romih et al., Ljubljana, Slovenia. In Histochem Cell Biol, 2011
The despites a lower level of expression, UPII maintain its plaque association in urothelial preneoplastic lesions.
Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
Rodriguez et al., Lanzhou, China. In Urol Oncol, 2010
combination of prostate stem cell antigen enhancer and uroplakin II promoter is feasible in constructing bladder cancer-specific vectors
Mutation analyses of Uroplakin II in children with renal tract malformations.
Woolf et al., London, United Kingdom. In Nephrol Dial Transplant, 2006
study offers no definitive support for uroplakin II mutations causing human renal tract malformations
The bladder as a bioreactor: urothelium production and secretion of growth hormone into urine.
Sun et al., Beltsville, United States. In Nat Biotechnol, 1998
Using a 3.6-kb promoter of mouse uroplakin II gene, we have generated transgenic mice that express human growth hormone (hGH) in their bladder epithelium, resulting in its secretion into the urine at 100-500 ng/ml.
Formation of asymmetric unit membrane during urothelial differentiation.
Wu et al., New York City, United States. In Mol Biol Rep, 1995
Studies of the protease sensitivity of the different subdomains of uroplakins and other considerations suggest that UPIa and UPIb have 4 transmembrane domains, while UPII and UPIII have only one transmembrane domain.
share on facebooktweetadd +1mail to friends